MRNA · Healthcare
Moderna, Inc.
Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window
News · 2026-08-19
- Regulatory Approval MilestonesImportance 71 · Surprise 60The FDA approved Moderna’s mFlusiva, the first mRNA flu vaccine in the United States for adults aged 50 and older. The approval opens a new seasonal influenza market and expands Moderna’s commercial portfolio beyond…
- Product / Drug Pipeline ProgressImportance 30 · Surprise 42Moderna and Merck reported positive Phase 3 results for intismeran autogene, also known as intismeran, V940, or mRNA-4157, combined with Merck’s KEYTRUDA in high-risk melanoma patients. The individualized mRNA…
News · 2026-08-17
- Regulatory Approval MilestonesImportance 71 · Surprise 60The FDA approved Moderna’s mFlusiva, the first mRNA flu vaccine in the United States for adults aged 50 and older. The approval opens a new seasonal influenza market and expands Moderna’s commercial portfolio beyond…
- Product / Drug Pipeline ProgressImportance 30 · Surprise 42Moderna and Merck reported positive Phase 3 results for intismeran autogene, also known as intismeran, V940, or mRNA-4157, combined with Merck’s KEYTRUDA in high-risk melanoma patients. The individualized mRNA…
News · 2026-08-14
- Licensing / Collaboration DealsImportance 34 · Surprise 42Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates…
News · 2026-08-12
- Licensing / Collaboration DealsImportance 34 · Surprise 42Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates…
News · 2026-08-11
- Litigation Settlement ExposureImportance 64 · Surprise 42Moderna recently agreed to pay Arbutus Biopharma $178 million to settle a patent-infringement dispute involving intellectual property relevant to Moderna’s mRNA platform. The settlement represents a material litigation…
News · 2026-08-10
- Regulatory Approval MilestonesImportance 71 · Surprise 60The U.S. Food and Drug Administration approved Moderna’s mRNA-based seasonal influenza vaccine, mFLUSIVA, during the week ended August 15, 2026. Third-party reporting described the approval as a late-stage commercial…
- Product / Drug Pipeline ProgressImportance 50 · Surprise 24Moderna’s valuation is described as dependent on successful execution and rapid commercialization of its late-stage pipeline. Oncology and rare-disease assets are expected by one third-party analysis to generate…
- Licensing / Collaboration DealsImportance 34 · Surprise 42Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates…
News · 2026-08-07
- Revenue Performance and MixImportance 74 · Surprise 32Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up…
- Guidance / OutlookImportance 59 · Surprise 32On its second-quarter 2026 earnings call, Moderna reiterated a target of up to 10% revenue growth for full-year 2026. Management also tightened its cost-of-sales and research-and-development guidance while emphasizing…
News · 2026-08-05
- Regulatory Approval MilestonesImportance 44 · Surprise 60The U.S. Food and Drug Administration approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine. It is authorized for adults aged 50 and older, with traditional approval for ages 50–64…
- Operating Expense TrendsImportance 37 · Surprise 42Moderna’s second-quarter 2026 earnings call emphasized cost reductions alongside pipeline investment. Management tightened its 2026 cost-of-sales and research-and-development guidance, although the digest did not…
- Litigation and Legal RiskImportance 37 · Surprise 42Moderna appealed a district court judgment concerning alleged patent infringement related to its COVID-19 vaccines to the U.S. Court of Appeals for the Federal Circuit. The company argues under 28 U.S.C. §1498(a) that…
News · 2026-08-04
- Revenue Performance and MixImportance 74 · Surprise 32Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up…
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Moderna initiated a Phase 1 clinical trial in Canada for mRNA-1469, an investigational vaccine against Bundibugyo ebolavirus disease. The study is expected to enroll approximately 80 healthy adults and will evaluate…
News · 2026-08-03
- Market Demand TrendsImportance 20 · Surprise 24Moderna continues to face weak demand for its COVID-19 vaccines as pandemic-era sales decline. COVID vaccine sales remain a significant influence on the company’s top line, creating pressure as Moderna transitions…
News · 2026-08-02
- Market Demand TrendsImportance 20 · Surprise 24Moderna continues to face weak demand for its COVID-19 vaccines as pandemic-era sales decline. COVID vaccine sales remain a significant influence on the company’s top line, creating pressure as Moderna transitions…
News · 2026-08-01
- Operating Expense TrendsImportance 64 · Surprise 42Moderna improved its 2026 GAAP operating expense outlook by approximately $200 million from its previous estimate. The company said it is continuing to reduce costs while advancing programs in respiratory vaccines,…
10-Q · 2026-07-31
- Liquidity and Cash PositionImportance 73 · Surprise 66Cash, cash equivalents and investments totaled $6.91 billion at June 30, 2026, down $1.2 billion, or 15%, from December 31, 2025, primarily due to $1.2 billion of operating cash outflows and $99 million of property and…
- Litigation Settlement ExposureImportance 71 · Surprise 60Moderna recorded $884 million of third-party royalty and amortization expense during the six months ended June 30, 2026 related to the Arbutus and Genevant litigation settlement. The company accrued a $950 million…
- Market Demand TrendsImportance 69 · Surprise 64Second-quarter net product sales declined 18% year over year, primarily because of lower COVID vaccine sales in the United States and South America, partially offset by deliveries in the United Kingdom. For the first…
- Guidance / OutlookImportance 69 · Surprise 60Moderna expects product sales to return to growth in 2026, supported by the full-year effect of long-term strategic partnerships with government entities. For 2026, management anticipates a modest decrease in cost of…
- Revenue Performance and MixImportance 69 · Surprise 64Second-quarter 2026 total revenue was $145 million, up 2% from $142 million in the second quarter of 2025. Net product sales declined $20 million, or 18%, primarily because of lower COVID vaccine sales in the United…
- Outstanding IndebtednessImportance 64 · Surprise 42Moderna’s November 2025 Credit and Guaranty Agreement provides a senior secured term-loan facility with aggregate commitments of $1.5 billion. The initial term loan matures on November 24, 2030, and the facility…
- Operating Expense TrendsImportance 59 · Surprise 48Second-quarter 2026 research and development expense decreased $49 million, or 7%, while six-month expense decreased $256 million, or 16%, year over year. Six-month R&D reductions included $119 million less clinical…
- Gross Margin DriversImportance 59 · Surprise 48Second-quarter 2026 cost of sales was $93 million and included $41 million of inventory write-downs, $23 million of unutilized manufacturing capacity costs, and $11 million of third-party royalties. Cost of sales…
- Income Tax Rate ChangesImportance 56 · Surprise 46Provision for income taxes increased $8 million, or 114%, in the second quarter of 2026 and $10 million, or 71%, in the first six months. The effective tax rates were negative 1.9% for the quarter and negative 1.1% for…
- Licensing / Collaboration DealsImportance 52 · Surprise 42In January 2026, Moderna entered into a worldwide exclusive, royalty-bearing license with Recordati S.p.A. for the investigational propionic acidemia therapeutic mRNA-3927. Moderna received an upfront payment in the…
- Capital ExpendituresImportance 41 · Surprise 48Moderna purchased $99 million of property and equipment during the first six months of 2026. The purchases supported facilities, manufacturing and laboratory equipment, and computer equipment and software. Capital…
- Regulatory Approval MilestonesImportance 38 · Surprise 60The European Commission authorized mCOMBRIAX, Moderna’s influenza-plus-COVID vaccine, for individuals aged 50 and older in April 2026. The authorization is valid across all 27 European Union member states, Iceland,…
- Product / Drug Pipeline ProgressImportance 23 · Surprise 24Moderna reported 26 development candidates across 36 clinical development programs spanning infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its intismeran autogene program, mRNA-4157,…
- Supply Chain And InventoryImportance 20 · Surprise 24Moderna held inventory for its COVID and RSV vaccines, including raw materials, work in progress and finished goods, as of June 30, 2026. Inventory write-downs were primarily related to inventory exceeding expected…
- Manufacturing And CapacityImportance 16 · Surprise 6Moderna describes its integrated manufacturing capabilities as enabling rapid clinical and commercial production at scale. The company manufactures across its mRNA platform while developing medicines in infectious…
- Distribution ChannelsImportance 6 · Surprise 6Moderna sells its COVID and RSV vaccines to commercial customers, governments and international organizations. In the United States, sales are primarily made through wholesalers and distributors, with a smaller portion…
8-K · 2026-07-31
- Guidance / OutlookImportance 80 · Surprise 68Moderna reiterated its plan to deliver up to 10% revenue growth in 2026 from 2025 revenue. The company lowered expected 2026 GAAP operating expenses by approximately $0.2 billion, including reducing projected research…
- Litigation Settlement ExposureImportance 75 · Surprise 60Moderna paid $950 million in July 2026 related to a litigation settlement announced in the first quarter of 2026. The company’s 2026 cost-of-sales outlook includes a $0.9 billion non-recurring litigation settlement…
- Gross Margin DriversImportance 73 · Surprise 66Second-quarter 2026 cost of sales was $93 million, equal to approximately 64% of revenue. Cost of sales decreased 22% year over year from $119 million, primarily because lower unutilized manufacturing capacity costs…
- Capital Expenditures ProgramImportance 70 · Surprise 40Moderna expects 2026 capital expenditures of $0.2 billion to $0.3 billion. Six-month 2026 purchases of property, plant and equipment were $99 million, compared with $120 million in the first six months of 2025. The…
- Liquidity and Cash PositionImportance 61 · Surprise 32Cash, cash equivalents and investments totaled $6.9 billion at June 30, 2026, down from $7.5 billion at March 31, 2026. Six-month net cash used in operating activities was $1.156 billion, compared with $1.956 billion…
- Operating Expense TrendsImportance 55 · Surprise 50Second-quarter 2026 research and development expense was $651 million, down 7% from $700 million in the second quarter of 2025. The R&D decline was driven by lower clinical development costs after several late-stage…
- Manufacturing And CapacityImportance 52 · Surprise 42Moderna incurred $23 million of unutilized manufacturing-capacity costs in the second quarter, indicating that production capacity remained underused. Unutilized-capacity costs declined from the prior year as continued…
- Regulatory Approval MilestonesImportance 44 · Surprise 60Moderna received European Commission marketing authorization for the mCOMBRIAX seasonal flu and COVID combination vaccine. Regulatory filings for mRNA-1083 are under review in Japan, Canada and Australia, while…
- Licensing / Collaboration DealsImportance 40 · Surprise 42Moderna signed a Brazil collaboration with a local manufacturer supporting a supply agreement for COVID vaccines. In the European Union, Moderna signed a joint procurement contract with the European Commission on…
- Geographic Market CommentaryImportance 38 · Surprise 24Moderna reported that lower COVID vaccine sales in the United States and South America were offset by deliveries in the United Kingdom under a long-term strategic government partnership. The company’s second-quarter…
- Revenue Performance and MixImportance 31 · Surprise 32Second-quarter 2026 revenue was $145 million, up 2% from $142 million in the second quarter of 2025. Net product sales declined to $94 million from $114 million, while other revenue increased to $51 million from $28…
- Product / Drug Pipeline ProgressImportance 30 · Surprise 42Moderna’s late-stage pipeline spans infectious-disease vaccines, oncology therapeutics and rare-disease treatments. The Phase 3 mRNA-1403 norovirus study did not meet statistical criteria for early success at interim…
News · 2026-07-31
- Guidance / OutlookImportance 85 · Surprise 76Moderna reiterated its 2026 target of up to 10% revenue growth. The company reduced its 2026 GAAP operating-expense outlook by approximately $200 million from its previous estimate. It also raised expected year-end…
- Liquidity and Cash PositionImportance 75 · Surprise 60Moderna improved its expected 2026 year-end cash balance to $4.7 billion-$5.2 billion. The company held $6.91 billion in cash and investments while reporting a $782 million second-quarter GAAP net loss. The higher cash…
- Litigation Settlement ExposureImportance 71 · Surprise 60Moderna recognized approximately $884 million of royalties related to a $950 million patent settlement with Arbutus and Genevant. The royalties materially increased cost of sales and contributed to a six-month 2026 net…
- Revenue Performance and MixImportance 65 · Surprise 32Moderna reported second-quarter 2026 revenue of $145 million, up 2.1% year over year and above the high end of its prior guidance range. Revenue remained heavily influenced by COVID-19 vaccine sales, while the company…
- Operating Expense TrendsImportance 64 · Surprise 42Moderna improved its 2026 GAAP operating expense outlook by approximately $200 million from its previous estimate. The company said it is continuing to reduce costs while advancing programs in respiratory vaccines,…
- Regulatory Approval MilestonesImportance 47 · Surprise 60Moderna is awaiting a potential U.S. Food and Drug Administration decision on mFLUSIVA, its seasonal influenza vaccine candidate. The Prescription Drug User Fee Act (PDUFA) action date is August 5, 2026. Approval would…
- Product / Drug Pipeline ProgressImportance 40 · Surprise 42Moderna’s mRNA-1403 norovirus vaccine candidate did not meet the statistical criteria for early success in a Phase 3 interim analysis. The blinded study remains ongoing, and Moderna is preparing to enroll an additional…
- Market Demand TrendsImportance 20 · Surprise 24Moderna continues to face weak demand for its COVID-19 vaccines as pandemic-era sales decline. COVID vaccine sales remain a significant influence on the company’s top line, creating pressure as Moderna transitions…
News · 2026-07-30
- Revenue Performance and MixImportance 69 · Surprise 64Moderna reported first-quarter 2026 revenue of $389 million, up 260.2% year over year. The company generated $3.0 billion of revenue in 2025, down sharply from pandemic-era levels. Messenger RNA (mRNA) Medicines…
- Guidance / OutlookImportance 52 · Surprise 30Analysts expect Moderna to report second-quarter 2026 revenue of approximately $103 million on July 31, 2026. Forecasts imply a 24.8% to 28% year-over-year revenue decline and a loss of roughly $1.97 to $2.00 per…
- Market Demand TrendsImportance 44 · Surprise 24Moderna remains heavily dependent on demand for COVID-19 vaccines, particularly its flagship Spikevax product, as pandemic-era demand has declined. Third-party coverage identifies vaccine sales as a central focus for…
News · 2026-07-29
- Product / Drug Pipeline ProgressImportance 31 · Surprise 42Moderna’s near-term product strategy includes commercialization plans for newer vaccines such as mCombriax and the seasonal influenza candidate mRNA-1010. Coverage also highlights updates to Moderna’s personalized…